Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists

Laurie Bergstrom, David E. Yocum, Neil M. Ampel, Isidro Villanueva, Jeffrey R Lisse, Oscar Gluck, John Tesser, James Posever, Margaret Miller, Julio Araujo, Dana M. Kageyama, Martin Berry, Linda Karl, Christianne M. Yung

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Objective. To describe a group of patients who were treated with tumor necrosis factor α (TNFα) antagonists and who developed coccidioidomycosis, and to test the hypothesis that patients with inflammatory arthritis receiving TNFα antagonist therapy are at higher risk for developing symptomatic coccidioidomycosis. Methods. Cases of coccidioidomycosis were identified and reviewed from among patients receiving TNFα antagonist therapy from May 1998 through February 2003 in 5 practices within the areas endemic for coccidioidomycosis (Arizona, California, and Nevada). In addition, the relative risk of developing symptomatic coccidioidomycosis was calculated in patients with inflammatory arthritis who were receiving treatment with infliximab, in comparison with patients with inflammatory arthritis who were not receiving infliximab, from January 2000 to February 2003 in a single medical center. Results. Thirteen cases of documented coccidioidomycosis were associated with TNFα antagonist therapy. Twelve cases were associated with the use of infliximab and 1 case with etanercept. Among the cohort of patients from a single medical center, 7 of the 247 patients receiving infliximab and 4 of the 738 patients receiving other therapies developed symptomatic coccidioidomycosis (relative risk 5.23, 95% confidence interval 1.54-17.71; P < 0.01). Conclusion. Patients with inflammatory arthritis who are undergoing treatment with infliximab appear to be at higher risk for developing symptomatic coccidioidomycosis as compared with those not receiving infliximab.

Original languageEnglish (US)
Pages (from-to)1959-1966
Number of pages8
JournalArthritis and Rheumatism
Volume50
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Coccidioidomycosis
Tumor Necrosis Factor-alpha
Arthritis
Therapeutics
Infliximab
Confidence Intervals

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. / Bergstrom, Laurie; Yocum, David E.; Ampel, Neil M.; Villanueva, Isidro; Lisse, Jeffrey R; Gluck, Oscar; Tesser, John; Posever, James; Miller, Margaret; Araujo, Julio; Kageyama, Dana M.; Berry, Martin; Karl, Linda; Yung, Christianne M.

In: Arthritis and Rheumatism, Vol. 50, No. 6, 06.2004, p. 1959-1966.

Research output: Contribution to journalArticle

Bergstrom, L, Yocum, DE, Ampel, NM, Villanueva, I, Lisse, JR, Gluck, O, Tesser, J, Posever, J, Miller, M, Araujo, J, Kageyama, DM, Berry, M, Karl, L & Yung, CM 2004, 'Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists', Arthritis and Rheumatism, vol. 50, no. 6, pp. 1959-1966. https://doi.org/10.1002/art.20454
Bergstrom, Laurie ; Yocum, David E. ; Ampel, Neil M. ; Villanueva, Isidro ; Lisse, Jeffrey R ; Gluck, Oscar ; Tesser, John ; Posever, James ; Miller, Margaret ; Araujo, Julio ; Kageyama, Dana M. ; Berry, Martin ; Karl, Linda ; Yung, Christianne M. / Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. In: Arthritis and Rheumatism. 2004 ; Vol. 50, No. 6. pp. 1959-1966.
@article{bde213fc012b4e2c85ea9ee1ec500d74,
title = "Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists",
abstract = "Objective. To describe a group of patients who were treated with tumor necrosis factor α (TNFα) antagonists and who developed coccidioidomycosis, and to test the hypothesis that patients with inflammatory arthritis receiving TNFα antagonist therapy are at higher risk for developing symptomatic coccidioidomycosis. Methods. Cases of coccidioidomycosis were identified and reviewed from among patients receiving TNFα antagonist therapy from May 1998 through February 2003 in 5 practices within the areas endemic for coccidioidomycosis (Arizona, California, and Nevada). In addition, the relative risk of developing symptomatic coccidioidomycosis was calculated in patients with inflammatory arthritis who were receiving treatment with infliximab, in comparison with patients with inflammatory arthritis who were not receiving infliximab, from January 2000 to February 2003 in a single medical center. Results. Thirteen cases of documented coccidioidomycosis were associated with TNFα antagonist therapy. Twelve cases were associated with the use of infliximab and 1 case with etanercept. Among the cohort of patients from a single medical center, 7 of the 247 patients receiving infliximab and 4 of the 738 patients receiving other therapies developed symptomatic coccidioidomycosis (relative risk 5.23, 95{\%} confidence interval 1.54-17.71; P < 0.01). Conclusion. Patients with inflammatory arthritis who are undergoing treatment with infliximab appear to be at higher risk for developing symptomatic coccidioidomycosis as compared with those not receiving infliximab.",
author = "Laurie Bergstrom and Yocum, {David E.} and Ampel, {Neil M.} and Isidro Villanueva and Lisse, {Jeffrey R} and Oscar Gluck and John Tesser and James Posever and Margaret Miller and Julio Araujo and Kageyama, {Dana M.} and Martin Berry and Linda Karl and Yung, {Christianne M.}",
year = "2004",
month = "6",
doi = "10.1002/art.20454",
language = "English (US)",
volume = "50",
pages = "1959--1966",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists

AU - Bergstrom, Laurie

AU - Yocum, David E.

AU - Ampel, Neil M.

AU - Villanueva, Isidro

AU - Lisse, Jeffrey R

AU - Gluck, Oscar

AU - Tesser, John

AU - Posever, James

AU - Miller, Margaret

AU - Araujo, Julio

AU - Kageyama, Dana M.

AU - Berry, Martin

AU - Karl, Linda

AU - Yung, Christianne M.

PY - 2004/6

Y1 - 2004/6

N2 - Objective. To describe a group of patients who were treated with tumor necrosis factor α (TNFα) antagonists and who developed coccidioidomycosis, and to test the hypothesis that patients with inflammatory arthritis receiving TNFα antagonist therapy are at higher risk for developing symptomatic coccidioidomycosis. Methods. Cases of coccidioidomycosis were identified and reviewed from among patients receiving TNFα antagonist therapy from May 1998 through February 2003 in 5 practices within the areas endemic for coccidioidomycosis (Arizona, California, and Nevada). In addition, the relative risk of developing symptomatic coccidioidomycosis was calculated in patients with inflammatory arthritis who were receiving treatment with infliximab, in comparison with patients with inflammatory arthritis who were not receiving infliximab, from January 2000 to February 2003 in a single medical center. Results. Thirteen cases of documented coccidioidomycosis were associated with TNFα antagonist therapy. Twelve cases were associated with the use of infliximab and 1 case with etanercept. Among the cohort of patients from a single medical center, 7 of the 247 patients receiving infliximab and 4 of the 738 patients receiving other therapies developed symptomatic coccidioidomycosis (relative risk 5.23, 95% confidence interval 1.54-17.71; P < 0.01). Conclusion. Patients with inflammatory arthritis who are undergoing treatment with infliximab appear to be at higher risk for developing symptomatic coccidioidomycosis as compared with those not receiving infliximab.

AB - Objective. To describe a group of patients who were treated with tumor necrosis factor α (TNFα) antagonists and who developed coccidioidomycosis, and to test the hypothesis that patients with inflammatory arthritis receiving TNFα antagonist therapy are at higher risk for developing symptomatic coccidioidomycosis. Methods. Cases of coccidioidomycosis were identified and reviewed from among patients receiving TNFα antagonist therapy from May 1998 through February 2003 in 5 practices within the areas endemic for coccidioidomycosis (Arizona, California, and Nevada). In addition, the relative risk of developing symptomatic coccidioidomycosis was calculated in patients with inflammatory arthritis who were receiving treatment with infliximab, in comparison with patients with inflammatory arthritis who were not receiving infliximab, from January 2000 to February 2003 in a single medical center. Results. Thirteen cases of documented coccidioidomycosis were associated with TNFα antagonist therapy. Twelve cases were associated with the use of infliximab and 1 case with etanercept. Among the cohort of patients from a single medical center, 7 of the 247 patients receiving infliximab and 4 of the 738 patients receiving other therapies developed symptomatic coccidioidomycosis (relative risk 5.23, 95% confidence interval 1.54-17.71; P < 0.01). Conclusion. Patients with inflammatory arthritis who are undergoing treatment with infliximab appear to be at higher risk for developing symptomatic coccidioidomycosis as compared with those not receiving infliximab.

UR - http://www.scopus.com/inward/record.url?scp=2642541034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642541034&partnerID=8YFLogxK

U2 - 10.1002/art.20454

DO - 10.1002/art.20454

M3 - Article

C2 - 15188373

AN - SCOPUS:2642541034

VL - 50

SP - 1959

EP - 1966

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 6

ER -